Flourish Research Invests in Valkyrie Clinical Trials
October 6, 2025
Flourish Research, a Genstar Capital-backed multi-site clinical trial organization, has made a strategic investment in Valkyrie Clinical Trials to establish a meaningful presence in oncology. Valkyrie, founded by Dr. David Berz and operating three sites in Los Angeles, will leverage Flourish's national network and infrastructure to accelerate oncology trial access and patient recruitment.
- Buyers
- Flourish Research, Genstar Capital
- Targets
- Valkyrie Clinical Trials
- Platforms
- Flourish Research
- Industry
- Healthcare Services
- Location
- California, United States
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
Flourish Research (NMS Capital-backed) Acquires Valley Clinical Trials
September 15, 2023
Healthcare Services
NMS Capital–backed Flourish Research has acquired Valley Clinical Trials, a three-site clinical research organization in Los Angeles County focused on cardiology, metabolic and related therapeutic areas. The deal — Flourish’s ninth acquisition since 2021 — expands the platform’s West Coast footprint; terms were not disclosed and Valley’s founder and management will remain in their roles.
-
Genstar Capital Acquires Majority Stake in Flourish Research
September 18, 2024
Healthcare Services
Genstar Capital has made a strategic majority investment in Flourish Research, a multi-site clinical trial organization headquartered in Apex, North Carolina. The transaction represents an exit for NMS Capital, which built Flourish into a 24-site network with ~150 investigators and scaled the business through infrastructure investments and acquisitions.
-
Flourish Research Acquires Diablo Clinical Research
February 18, 2025
Healthcare Services
Flourish Research, a multi-site clinical trial organization headquartered in Apex, North Carolina, has acquired Diablo Clinical Research, a Walnut Creek, California-based clinical research facility established in 1995 that has conducted more than 1,000 phase I–IV trials and medical device studies. The add-on acquisition (Flourish is PE-backed by Genstar Capital) expands Flourish's geographic footprint and therapeutic-area capabilities, particularly in endocrinology, cardiovascular and metabolic research.
-
Flourish Research (NMS Capital) Recapitalizes Keystone Clinical Studies
October 6, 2022
Healthcare Services
Flourish Research, a portfolio company of NMS Capital, partnered with Keystone Clinical Studies' management in a recapitalization transaction. Keystone, a Plymouth Meeting, Pennsylvania-based clinical research site focused on Alzheimer’s disease and CNS conditions, will continue to be led by founder Dr. Cherian Verghese as part of the Flourish platform to expand CNS capabilities and enter the Philadelphia market.
-
NMS-backed Flourish Research Recapitalizes Great Lakes Clinical Trials and Clinical Site Partners
January 12, 2022
Healthcare Services
NMS Capital portfolio company Flourish Research completed recapitalizations of Great Lakes Clinical Trials and Clinical Site Partners, expanding its multi-site clinical trial network across Illinois, Florida and Texas. The deals (terms undisclosed) add site capacity and management teams to Flourish Research as the platform pursues network consolidation, improved operational efficiencies and accelerated growth.
-
Flourish Research / NMS Capital Recapitalize Excel Medical Clinical Trials
October 14, 2021
Healthcare Services
NMS Capital portfolio company Flourish Research partnered with Excel Medical Clinical Trials in a recapitalization. The Boca Raton, Florida-based clinical research site, founded by Dr. Seth Baum and focused on cardiology indications, will join Flourish's site network to expand the platform's geographic footprint and therapeutic capabilities; terms were not disclosed and management will remain in place.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.